Stockreport

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depr...

Alzamend Neuro, Inc.  (ALZN) 
PDF Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the studyHead-to-head study of AL001 versus a marketed lithiu [Read more]